Galmed Pharmaceuticals Ltd.
GLMDGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for liver diseases. The company's lead product candidate, Aramchol, is a bile acid derivative developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Galmed also explores other therapeutic options targeting liver and metabolic conditions.
Company News
Galmed Pharmaceuticals announced a definitive agreement to acquire Colospan Ltd., a medical device company, for $2.5 million in cash and $2.0 million in Galmed shares. The acquisition combines Galmed's public company infrastructure with Colospan's CG-100 intraluminal bypass device, which has FDA Breakthrough Device Designation and is CE marked in...
Galmed Pharmaceuticals announced positive Phase 1 PK study results showing that 400mg of Aramchol meglumine (AM) oral formulation achieves approximately 5-fold greater bioavailability compared to 300mg Aramchol free acid tablets. The new once-daily lower dose formulation could improve patient compliance, reduce manufacturing costs by ~50%, and st...
Galmed Pharmaceuticals, a clinical-stage biopharmaceutical company, filed its annual report on Form 20-F with the SEC for fiscal year 2025. The company is focused on developing Aramchol for liver and cardiometabolic diseases, with ongoing clinical trials for NASH treatment and exploration of combination therapies. The filing includes extensive fo...
Galmed Pharmaceuticals reported significant bioavailability results for Aramchol meglumine, showing 3-5 fold increase compared to previous tablets, potentially enabling once-daily dosing and reducing drug costs.
Galmed Pharmaceuticals plans to invest up to $10 million in digital assets, engaging Tectona Ltd. to manage a new crypto treasury strategy aimed at enhancing capital efficiency and shareholder value.
